FAPi PET/CT Imaging to Identify Fibrosis in Immune-Mediated Inflammatory Diseases

Immune-mediated inflammatory diseases (IMIDs) are characterized by chronic systemic inflammation and multi-organ involvement. Fibrosis formation in IMIDs can cause tissue destruction and subsequently organ malfunction. Fibroblast activation protein inhibitor positron emission tomography/computed tom...

Full description

Saved in:
Bibliographic Details
Main Authors: Dalia A. Lartey, Lynn A. Schilder, Gerben J. C. Zwezerijnen, Geert R. A. M. D’Haens, Joep Grootjans, Mark Löwenberg
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Biomedicines
Subjects:
Online Access:https://www.mdpi.com/2227-9059/13/4/775
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849712332725288960
author Dalia A. Lartey
Lynn A. Schilder
Gerben J. C. Zwezerijnen
Geert R. A. M. D’Haens
Joep Grootjans
Mark Löwenberg
author_facet Dalia A. Lartey
Lynn A. Schilder
Gerben J. C. Zwezerijnen
Geert R. A. M. D’Haens
Joep Grootjans
Mark Löwenberg
author_sort Dalia A. Lartey
collection DOAJ
description Immune-mediated inflammatory diseases (IMIDs) are characterized by chronic systemic inflammation and multi-organ involvement. Fibrosis formation in IMIDs can cause tissue destruction and subsequently organ malfunction. Fibroblast activation protein inhibitor positron emission tomography/computed tomography (FAPi PET/CT) represents a novel imaging technique that holds great potential to visualize in vivo fibrosis. We here provide an overview of available evidence on FAPi PET/CT imaging to visualize fibrosis in various IMIDs, including interstitial lung diseases, immunoglobulin G4-related diseases, cardiovascular diseases, kidney diseases, and gastrointestinal diseases. FAPi PET/CT imaging demonstrates high sensitivity in detecting early fibrosis, correlating with disease severity, across different IMIDs, showing superiority compared to conventional imaging modalities. Although FAPi PET/CT might be a useful tool to assess fibrosis formation, thereby aiding in grading disease severity and staging, future studies should include larger sample sizes in a broad variety of IMIDs with emphasis on the optimization of imaging protocols to further validate its diagnostic value.
format Article
id doaj-art-80c800dfe46745e8b47079a2cdd122ad
institution DOAJ
issn 2227-9059
language English
publishDate 2025-03-01
publisher MDPI AG
record_format Article
series Biomedicines
spelling doaj-art-80c800dfe46745e8b47079a2cdd122ad2025-08-20T03:14:17ZengMDPI AGBiomedicines2227-90592025-03-0113477510.3390/biomedicines13040775FAPi PET/CT Imaging to Identify Fibrosis in Immune-Mediated Inflammatory DiseasesDalia A. Lartey0Lynn A. Schilder1Gerben J. C. Zwezerijnen2Geert R. A. M. D’Haens3Joep Grootjans4Mark Löwenberg5Laboratory of Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam University Medical Centers, 1081 BT Amsterdam, The NetherlandsDepartment of Gastroenterology and Hepatology, Amsterdam University Medical Centers, 1081 HV Amsterdam, The NetherlandsDepartment of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, 1081 HV Amsterdam, The NetherlandsDepartment of Gastroenterology and Hepatology, Amsterdam University Medical Centers, 1081 HV Amsterdam, The NetherlandsLaboratory of Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam University Medical Centers, 1081 BT Amsterdam, The NetherlandsDepartment of Gastroenterology and Hepatology, Amsterdam University Medical Centers, 1081 HV Amsterdam, The NetherlandsImmune-mediated inflammatory diseases (IMIDs) are characterized by chronic systemic inflammation and multi-organ involvement. Fibrosis formation in IMIDs can cause tissue destruction and subsequently organ malfunction. Fibroblast activation protein inhibitor positron emission tomography/computed tomography (FAPi PET/CT) represents a novel imaging technique that holds great potential to visualize in vivo fibrosis. We here provide an overview of available evidence on FAPi PET/CT imaging to visualize fibrosis in various IMIDs, including interstitial lung diseases, immunoglobulin G4-related diseases, cardiovascular diseases, kidney diseases, and gastrointestinal diseases. FAPi PET/CT imaging demonstrates high sensitivity in detecting early fibrosis, correlating with disease severity, across different IMIDs, showing superiority compared to conventional imaging modalities. Although FAPi PET/CT might be a useful tool to assess fibrosis formation, thereby aiding in grading disease severity and staging, future studies should include larger sample sizes in a broad variety of IMIDs with emphasis on the optimization of imaging protocols to further validate its diagnostic value.https://www.mdpi.com/2227-9059/13/4/775fibrosisimmune-mediated inflammatory diseases (IMIDs)FAPi PET/CTfibroblast activation protein (FAP)positron emission tomography imaging
spellingShingle Dalia A. Lartey
Lynn A. Schilder
Gerben J. C. Zwezerijnen
Geert R. A. M. D’Haens
Joep Grootjans
Mark Löwenberg
FAPi PET/CT Imaging to Identify Fibrosis in Immune-Mediated Inflammatory Diseases
Biomedicines
fibrosis
immune-mediated inflammatory diseases (IMIDs)
FAPi PET/CT
fibroblast activation protein (FAP)
positron emission tomography imaging
title FAPi PET/CT Imaging to Identify Fibrosis in Immune-Mediated Inflammatory Diseases
title_full FAPi PET/CT Imaging to Identify Fibrosis in Immune-Mediated Inflammatory Diseases
title_fullStr FAPi PET/CT Imaging to Identify Fibrosis in Immune-Mediated Inflammatory Diseases
title_full_unstemmed FAPi PET/CT Imaging to Identify Fibrosis in Immune-Mediated Inflammatory Diseases
title_short FAPi PET/CT Imaging to Identify Fibrosis in Immune-Mediated Inflammatory Diseases
title_sort fapi pet ct imaging to identify fibrosis in immune mediated inflammatory diseases
topic fibrosis
immune-mediated inflammatory diseases (IMIDs)
FAPi PET/CT
fibroblast activation protein (FAP)
positron emission tomography imaging
url https://www.mdpi.com/2227-9059/13/4/775
work_keys_str_mv AT daliaalartey fapipetctimagingtoidentifyfibrosisinimmunemediatedinflammatorydiseases
AT lynnaschilder fapipetctimagingtoidentifyfibrosisinimmunemediatedinflammatorydiseases
AT gerbenjczwezerijnen fapipetctimagingtoidentifyfibrosisinimmunemediatedinflammatorydiseases
AT geertramdhaens fapipetctimagingtoidentifyfibrosisinimmunemediatedinflammatorydiseases
AT joepgrootjans fapipetctimagingtoidentifyfibrosisinimmunemediatedinflammatorydiseases
AT marklowenberg fapipetctimagingtoidentifyfibrosisinimmunemediatedinflammatorydiseases